NASDAQ:SBBP - Strongbridge Biopharma Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$7.60 -0.10 (-1.30 %)
(As of 05/21/2018 04:00 PM ET)
Previous Close$7.70
Today's Range$7.43 - $7.77
52-Week Range$4.05 - $9.25
Volume200,124 shs
Average Volume300,571 shs
Market Capitalization$350.62 million
P/E Ratio-5.24
Dividend YieldN/A
Beta1.04

About Strongbridge Biopharma (NASDAQ:SBBP)

Strongbridge Biopharma logoStrongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency in the United States and Canada. Its clinical-stage product candidates are Recorlev, a cortisol synthesis inhibitor, which is in a Phase III clinical trial that is used for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that is used for treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is headquartered in Trevose, Pennsylvania.

Receive SBBP News and Ratings via Email

Sign-up to receive the latest news and ratings for SBBP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SBBP
CUSIPN/A
Phone610-254-9200

Debt

Debt-to-Equity Ratio41.16
Current Ratio8.90
Quick Ratio8.74

Price-To-Earnings

Trailing P/E Ratio-5.24
Forward P/E Ratio-3.92
P/E GrowthN/A

Sales & Book Value

Annual Sales$7.05 million
Price / Sales49.08
Cash FlowN/A
Price / CashN/A
Book Value($0.30) per share
Price / Book-25.33

Profitability

EPS (Most Recent Fiscal Year)($1.45)
Net Income$-113,480,000.00
Net Margins-1,032.62%
Return on Equity-1,224.30%
Return on Assets-59.45%

Miscellaneous

Employees66
Outstanding Shares45,530,000

Strongbridge Biopharma (NASDAQ:SBBP) Frequently Asked Questions

What is Strongbridge Biopharma's stock symbol?

Strongbridge Biopharma trades on the NASDAQ under the ticker symbol "SBBP."

How were Strongbridge Biopharma's earnings last quarter?

Strongbridge Biopharma (NASDAQ:SBBP) posted its quarterly earnings data on Thursday, May, 10th. The biotechnology company reported ($0.66) EPS for the quarter, missing the Zacks' consensus estimate of ($0.41) by $0.25. The biotechnology company had revenue of $3.87 million for the quarter, compared to analyst estimates of $3.25 million. Strongbridge Biopharma had a negative net margin of 1,032.62% and a negative return on equity of 1,224.30%. View Strongbridge Biopharma's Earnings History.

When is Strongbridge Biopharma's next earnings date?

Strongbridge Biopharma is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Strongbridge Biopharma.

What price target have analysts set for SBBP?

3 brokers have issued 12 month target prices for Strongbridge Biopharma's shares. Their forecasts range from $12.00 to $18.00. On average, they expect Strongbridge Biopharma's share price to reach $14.6667 in the next twelve months. View Analyst Ratings for Strongbridge Biopharma.

What are Wall Street analysts saying about Strongbridge Biopharma stock?

Here are some recent quotes from research analysts about Strongbridge Biopharma stock:
  • 1. According to Zacks Investment Research, "Strongbridge Biopharma PLC is a biopharmaceutical company which develops, acquires and commercializes product candidates that target rare diseases. Its product candidate consists of COR-003, is a cortisol inhibitor, for the treatment of endogenous Cushing's syndrome, COR-004 and COR-005 to treat acromegaly, BP-2001, the treatment of diabetes which are in different clinical trial. Strongbridge Biopharma PLC is based in Trevose, Pennsylvania. " (5/12/2018)
  • 2. HC Wainwright analysts commented, "BioLife reported 1Q18 biopreservation media revenue of $3.8, up 22% sequentially and 61% y/y. Margin also continue to rise with increasing volume, coming in at 64% in 1Q. The company is cash flow positive and currently has $9.6M in cash on the balance sheet (including $2.6M from warrants exercised recently). Biolife’s valuation continues to rise as media revenue grows and the company becomes more deeply integrated into an evolving cell therapy space. We are increasing our outyear estimates for cell media revenue which increases our 12-month price target to $12, from $9.." (5/11/2018)
  • 3. Cantor Fitzgerald analysts commented, "Added Focus on RECORLEV into Mid-2108. Ahead of the mid-2018 SONICS top-line readout, we anticipate greater attention to shift towards the RECORLEV opportunity in Cushing’s syndrome. As a reminder, we believe Recorlev has demonstrated greater control over cortisol secretion over ketoconazole with fewer liabilities associated with liver enzyme elevations. Strongbridge plans to host an investor and analyst day on April 5, 2018, to discuss these opportunities and development progress. Following SONICS we anticipate data from LOGICS in 1Q19, a slight slippage from 4Q18, previously." (3/12/2018)

Who are some of Strongbridge Biopharma's key competitors?

Who are Strongbridge Biopharma's key executives?

Strongbridge Biopharma's management team includes the folowing people:
  • Mr. Matthew Pauls, CEO, Pres & Director (Age 47)
  • Mr. A. Brian Davis, Chief Financial Officer (Age 51)
  • Dr. Fredric Cohen, Chief Medical Officer (Age 53)
  • Dr. Per Marin M.D., Ph.D., Founder and Sr. Clinical Advisor
  • Mr. Peter J. Valentinsson, Sr. VP of Global Technical Operations

Has Strongbridge Biopharma been receiving favorable news coverage?

News articles about SBBP stock have been trending somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Strongbridge Biopharma earned a media sentiment score of 0.22 on Accern's scale. They also assigned news coverage about the biotechnology company an impact score of 46.40 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Who are Strongbridge Biopharma's major shareholders?

Strongbridge Biopharma's stock is owned by a number of of retail and institutional investors. Top institutional investors include Caxton Corp (11.81%), Lyon Street Capital LLC (6.99%), BlackRock Inc. (3.94%), Opaleye Management Inc. (3.49%), Harvest Capital Strategies LLC (1.81%) and Park West Asset Management LLC (1.72%). View Institutional Ownership Trends for Strongbridge Biopharma.

Which major investors are selling Strongbridge Biopharma stock?

SBBP stock was sold by a variety of institutional investors in the last quarter, including Tredje AP fonden and Caxton Corp. View Insider Buying and Selling for Strongbridge Biopharma.

Which major investors are buying Strongbridge Biopharma stock?

SBBP stock was acquired by a variety of institutional investors in the last quarter, including Lyon Street Capital LLC, Harvest Capital Strategies LLC, Park West Asset Management LLC, BlackRock Inc., Opaleye Management Inc., Millennium Management LLC, Wells Fargo & Company MN and Spark Investment Management LLC. View Insider Buying and Selling for Strongbridge Biopharma.

How do I buy shares of Strongbridge Biopharma?

Shares of SBBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Strongbridge Biopharma's stock price today?

One share of SBBP stock can currently be purchased for approximately $7.60.

How big of a company is Strongbridge Biopharma?

Strongbridge Biopharma has a market capitalization of $350.62 million and generates $7.05 million in revenue each year. The biotechnology company earns $-113,480,000.00 in net income (profit) each year or ($1.45) on an earnings per share basis. Strongbridge Biopharma employs 66 workers across the globe.

How can I contact Strongbridge Biopharma?

Strongbridge Biopharma's mailing address is 900 NORTHBROOK DRIVE SUITE 200, TREVOSE PA, 19053. The biotechnology company can be reached via phone at 610-254-9200 or via email at [email protected]


MarketBeat Community Rating for Strongbridge Biopharma (SBBP)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  146 (Vote Outperform)
Underperform Votes:  110 (Vote Underperform)
Total Votes:  256
MarketBeat's community ratings are surveys of what our community members think about Strongbridge Biopharma and other stocks. Vote "Outperform" if you believe SBBP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SBBP will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Strongbridge Biopharma (NASDAQ:SBBP) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Strongbridge Biopharma in the last 12 months. Their average twelve-month price target is $14.6667, suggesting that the stock has a possible upside of 92.98%. The high price target for SBBP is $18.00 and the low price target for SBBP is $12.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $14.6667$14.6667$14.6667$13.3333
Price Target Upside: 92.98% upside76.71% upside86.84% upside131.88% upside

Strongbridge Biopharma (NASDAQ:SBBP) Consensus Price Target History

Price Target History for Strongbridge Biopharma (NASDAQ:SBBP)

Strongbridge Biopharma (NASDAQ:SBBP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/11/2018HC WainwrightReiterated RatingBuyLowView Rating Details
5/10/2018Cantor FitzgeraldSet Price TargetBuy$14.00MediumView Rating Details
8/10/2017OppenheimerInitiated CoverageOutperform$12.00HighView Rating Details
12/28/2016JMP SecuritiesReiterated RatingOutperform$10.00N/AView Rating Details
(Data available from 5/21/2016 forward)

Earnings

Strongbridge Biopharma (NASDAQ:SBBP) Earnings History and Estimates Chart

Earnings by Quarter for Strongbridge Biopharma (NASDAQ:SBBP)

Strongbridge Biopharma (NASDAQ:SBBP) Earnings Estimates

2018 EPS Consensus Estimate: ($2.19)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.40)($0.40)($0.40)
Q2 20181($0.51)($0.51)($0.51)
Q3 20181($0.59)($0.59)($0.59)
Q4 20181($0.69)($0.69)($0.69)

Strongbridge Biopharma (NASDAQ SBBP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2018        
5/10/2018Q1 2018($0.41)($0.66)$3.25 million$3.87 millionViewListenView Earnings Details
3/12/2018Q4 2017($0.34)($0.34)$2.98 million$2.98 millionViewN/AView Earnings Details
11/14/2017Q3 2017($0.46)($0.39)$1.77 million$2.53 millionViewN/AView Earnings Details
8/7/2017Q2 2017($0.34)($0.34)$0.84 million$1.53 millionViewListenView Earnings Details
5/16/20173/31/2017($0.49)($0.33)ViewN/AView Earnings Details
3/27/2017Q4 2016($0.32)($0.25)ViewN/AView Earnings Details
12/23/2016Q2 2016($0.36)ViewN/AView Earnings Details
5/17/2016Q1($0.6270)($0.57)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Strongbridge Biopharma (NASDAQ:SBBP) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Strongbridge Biopharma (NASDAQ SBBP) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.20%
Institutional Ownership Percentage: 67.69%
Insider Trading History for Strongbridge Biopharma (NASDAQ:SBBP)
Institutional Ownership by Quarter for Strongbridge Biopharma (NASDAQ:SBBP)

Strongbridge Biopharma (NASDAQ SBBP) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Strongbridge Biopharma (NASDAQ SBBP) News Headlines

Source:
DateHeadline
 Analysts Expect Strongbridge Biopharma (SBBP) Will Announce Earnings of -$0.48 Per Share Analysts Expect Strongbridge Biopharma (SBBP) Will Announce Earnings of -$0.48 Per Share
www.americanbankingnews.com - May 20 at 11:14 PM
Brokers Set Expectations for Strongbridge Biopharmas FY2018 Earnings (SBBP)Brokers Set Expectations for Strongbridge Biopharma's FY2018 Earnings (SBBP)
www.americanbankingnews.com - May 16 at 8:07 AM
Strongbridge Biopharmas (SBBP) CEO Matthew Pauls on Q1 2018 Results - Earnings Call TranscriptStrongbridge Biopharma's (SBBP) CEO Matthew Pauls on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 13 at 4:50 PM
Strongbridge Biopharma (SBBP) Downgraded by Zacks Investment ResearchStrongbridge Biopharma (SBBP) Downgraded by Zacks Investment Research
www.americanbankingnews.com - May 12 at 4:23 PM
Strongbridge Biopharma (SBBP) Rating Lowered to Hold at BidaskClubStrongbridge Biopharma (SBBP) Rating Lowered to Hold at BidaskClub
www.americanbankingnews.com - May 12 at 7:35 AM
Strongbridge Biopharma (SBBP) Issues Quarterly  Earnings ResultsStrongbridge Biopharma (SBBP) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 11 at 9:39 PM
HC Wainwright Reiterates "Buy" Rating for Strongbridge Biopharma (SBBP)HC Wainwright Reiterates "Buy" Rating for Strongbridge Biopharma (SBBP)
www.americanbankingnews.com - May 11 at 6:25 PM
Edited Transcript of SBBP earnings conference call or presentation 10-May-18 12:30pm GMTEdited Transcript of SBBP earnings conference call or presentation 10-May-18 12:30pm GMT
finance.yahoo.com - May 11 at 10:12 AM
Cantor Fitzgerald Reiterates "$14.00" Price Target for Strongbridge Biopharma (SBBP)Cantor Fitzgerald Reiterates "$14.00" Price Target for Strongbridge Biopharma (SBBP)
www.americanbankingnews.com - May 10 at 5:53 PM
Strongbridge Biopharma beats by $0.07, beats on revenueStrongbridge Biopharma beats by $0.07, beats on revenue
seekingalpha.com - May 10 at 9:27 AM
Strongbridge Biopharma (SBBP) Upgraded by BidaskClub to BuyStrongbridge Biopharma (SBBP) Upgraded by BidaskClub to Buy
www.americanbankingnews.com - May 5 at 6:37 AM
Zacks: Brokerages Anticipate Strongbridge Biopharma (SBBP) Will Announce Quarterly Sales of $3.25 MillionZacks: Brokerages Anticipate Strongbridge Biopharma (SBBP) Will Announce Quarterly Sales of $3.25 Million
www.americanbankingnews.com - May 5 at 3:39 AM
Strongbridge Biopharma (SBBP) Receives Consensus Rating of "Buy" from BrokeragesStrongbridge Biopharma (SBBP) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 4 at 1:34 AM
Strongbridge Biopharma (SBBP) Expected to Announce Earnings of -$0.41 Per ShareStrongbridge Biopharma (SBBP) Expected to Announce Earnings of -$0.41 Per Share
www.americanbankingnews.com - May 3 at 6:17 PM
Strongbridge Biopharma (SBBP) Scheduled to Post Quarterly Earnings on ThursdayStrongbridge Biopharma (SBBP) Scheduled to Post Quarterly Earnings on Thursday
www.americanbankingnews.com - May 3 at 3:50 AM
Strongbridge Biopharma (SBBP) Rating Increased to Hold at ValuEngineStrongbridge Biopharma (SBBP) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - May 2 at 5:58 PM
Strongbridge Biopharma plc to Host First Quarter 2018 Financial Results Conference Call on May 10, 2018Strongbridge Biopharma plc to Host First Quarter 2018 Financial Results Conference Call on May 10, 2018
feeds.benzinga.com - April 26 at 7:57 AM
Strongbridge Biopharma (SBBP) Downgraded by BidaskClubStrongbridge Biopharma (SBBP) Downgraded by BidaskClub
www.americanbankingnews.com - April 21 at 7:24 AM
With A -133.52% Earnings Drop, Is Strongbridge Biopharma plc’s (NASDAQ:SBBP) A Concern?With A -133.52% Earnings Drop, Is Strongbridge Biopharma plc’s (NASDAQ:SBBP) A Concern?
finance.yahoo.com - April 20 at 9:24 AM
$3.25 Million in Sales Expected for Strongbridge Biopharma (SBBP) This Quarter$3.25 Million in Sales Expected for Strongbridge Biopharma (SBBP) This Quarter
www.americanbankingnews.com - April 18 at 3:56 AM
-$0.41 Earnings Per Share Expected for Strongbridge Biopharma (SBBP) This Quarter-$0.41 Earnings Per Share Expected for Strongbridge Biopharma (SBBP) This Quarter
www.americanbankingnews.com - April 16 at 11:18 AM
Strongbridge Biopharma (SBBP) Upgraded to Hold by Zacks Investment ResearchStrongbridge Biopharma (SBBP) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - April 12 at 11:17 AM
Strongbridge Biopharma (SBBP) Stock Rating Lowered by Zacks Investment ResearchStrongbridge Biopharma (SBBP) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 11 at 3:24 PM
Mediaplanet and Actor Micah Fowler Team Up to Raise Awareness for Rare DiseasesMediaplanet and Actor Micah Fowler Team Up to Raise Awareness for Rare Diseases
www.benzinga.com - April 11 at 9:51 AM
Strongbridge Biopharma (SBBP) Given Average Recommendation of "Buy" by AnalystsStrongbridge Biopharma (SBBP) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - April 9 at 1:41 AM
Strongbridge Biopharma (SBBP) Downgraded to "Sell" at ValuEngineStrongbridge Biopharma (SBBP) Downgraded to "Sell" at ValuEngine
www.americanbankingnews.com - April 8 at 10:46 AM
Strongbridge Biopharma (SBBP) Lifted to "Hold" at Zacks Investment ResearchStrongbridge Biopharma (SBBP) Lifted to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 6 at 11:07 AM
Strongbridge Biopharma (SBBP) PT Set at $14.00 by Cantor FitzgeraldStrongbridge Biopharma (SBBP) PT Set at $14.00 by Cantor Fitzgerald
www.americanbankingnews.com - April 5 at 3:30 PM
Strongbridge Biopharma (SBBP) Lowered to "Buy" at BidaskClubStrongbridge Biopharma (SBBP) Lowered to "Buy" at BidaskClub
www.americanbankingnews.com - April 5 at 12:30 AM
Strongbridge Bio (SBBP) Doses First Four Patients in LOGICS, Second Global Phase 3 Study of RECORLEV in Endogenous Cushings SyndromeStrongbridge Bio (SBBP) Doses First Four Patients in LOGICS, Second Global Phase 3 Study of RECORLEV in Endogenous Cushing's Syndrome
www.streetinsider.com - April 2 at 10:00 AM
Strongbridge Biopharma doses first four patients in LOGICS, a second global Phase 3 study of RECORLEV in endogenous CSStrongbridge Biopharma doses first four patients in LOGICS, a second global Phase 3 study of RECORLEV in endogenous CS
seekingalpha.com - April 2 at 10:00 AM
$3.25 Million in Sales Expected for Strongbridge Biopharma plc (SBBP) This Quarter$3.25 Million in Sales Expected for Strongbridge Biopharma plc (SBBP) This Quarter
www.americanbankingnews.com - April 1 at 4:00 AM
Strongbridge Biopharma plc (SBBP) Expected to Announce Earnings of -$0.41 Per ShareStrongbridge Biopharma plc (SBBP) Expected to Announce Earnings of -$0.41 Per Share
www.americanbankingnews.com - March 30 at 1:18 PM
Strongbridge Biopharma (SBBP) Stock Rating Upgraded by BidaskClubStrongbridge Biopharma (SBBP) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - March 28 at 9:16 PM
Strongbridge Biopharma (SBBP) Lifted to Strong-Buy at BidaskClubStrongbridge Biopharma (SBBP) Lifted to Strong-Buy at BidaskClub
www.americanbankingnews.com - March 22 at 12:22 PM
Teva Sued by Corcept Therapeutics over Patent Infringement ClaimTeva Sued by Corcept Therapeutics over Patent Infringement Claim
finance.yahoo.com - March 21 at 4:58 PM
Strongbridge Biopharma (SBBP) Announces Issuance of Patent for RECORLEVStrongbridge Biopharma (SBBP) Announces Issuance of Patent for RECORLEV
www.streetinsider.com - March 21 at 9:46 AM
Strongbridge Biopharma Announces Issuance of Patent for RECORLEV™ (levoketoconazole) for the Treatment of Cushing’s SyndromeStrongbridge Biopharma Announces Issuance of Patent for RECORLEV™ (levoketoconazole) for the Treatment of Cushing’s Syndrome
finance.yahoo.com - March 20 at 4:49 PM
Edited Transcript of SBBP earnings conference call or presentation 12-Mar-18 12:30pm GMTEdited Transcript of SBBP earnings conference call or presentation 12-Mar-18 12:30pm GMT
finance.yahoo.com - March 18 at 9:38 AM
Strongbridge Biopharma (SBBP) Rating Lowered to Sell at Zacks Investment ResearchStrongbridge Biopharma (SBBP) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - March 16 at 12:52 PM
Strongbridge Biopharma plc to Post FY2018 Earnings of ($1.38) Per Share, Cantor Fitzgerald Forecasts (SBBP)Strongbridge Biopharma plc to Post FY2018 Earnings of ($1.38) Per Share, Cantor Fitzgerald Forecasts (SBBP)
www.americanbankingnews.com - March 16 at 10:21 AM
Strongbridge Biopharma plc (SBBP) to Post Q1 2018 Earnings of ($0.40) Per Share, Oppenheimer ForecastsStrongbridge Biopharma plc (SBBP) to Post Q1 2018 Earnings of ($0.40) Per Share, Oppenheimer Forecasts
www.americanbankingnews.com - March 15 at 6:26 AM
Strongbridge Biopharma plc (SBBP) Given Average Recommendation of "Buy" by AnalystsStrongbridge Biopharma plc (SBBP) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - March 15 at 1:04 AM
BRIEF-Strongbridge Biopharma Plc Files For Resale Of Up To 26.5 Mln Ordinary Shares By The Selling ShareholdersBRIEF-Strongbridge Biopharma Plc Files For Resale Of Up To 26.5 Mln Ordinary Shares By The Selling Shareholders
www.reuters.com - March 13 at 10:50 AM
Strongbridge Biopharma (SBBP) Receives "Buy" Rating from Cantor FitzgeraldStrongbridge Biopharma (SBBP) Receives "Buy" Rating from Cantor Fitzgerald
www.americanbankingnews.com - March 12 at 12:53 PM
Stonepine Capital Management LLC Takes $2.50 Million Position in Strongbridge Biopharma plc (SBBP)Stonepine Capital Management LLC Takes $2.50 Million Position in Strongbridge Biopharma plc (SBBP)
www.americanbankingnews.com - March 6 at 10:02 AM
Hudson Bay Capital Management LP Invests $1.81 Million in Strongbridge Biopharma plc (SBBP) StockHudson Bay Capital Management LP Invests $1.81 Million in Strongbridge Biopharma plc (SBBP) Stock
www.americanbankingnews.com - March 2 at 12:49 PM
Strongbridge Biopharma plc (SBBP) Position Increased by Broadfin Capital LLCStrongbridge Biopharma plc (SBBP) Position Increased by Broadfin Capital LLC
www.americanbankingnews.com - March 2 at 5:08 AM
Strongbridge Biopharma plc to Host Conference Call on March 12, 2018 to Announce Fourth Quarter and Year-End 2017 Financial Results and Provide Corporate UpdateStrongbridge Biopharma plc to Host Conference Call on March 12, 2018 to Announce Fourth Quarter and Year-End 2017 Financial Results and Provide Corporate Update
finance.yahoo.com - February 28 at 9:44 AM
Strongbridge Biopharma plc Announces Underwriters’ Partial Exercise of Option to Purchase Additional SharesStrongbridge Biopharma plc Announces Underwriters’ Partial Exercise of Option to Purchase Additional Shares
finance.yahoo.com - February 26 at 9:36 AM

SEC Filings

Strongbridge Biopharma (NASDAQ:SBBP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Strongbridge Biopharma (NASDAQ:SBBP) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Strongbridge Biopharma (NASDAQ SBBP) Stock Chart for Monday, May, 21, 2018

Loading chart…

This page was last updated on 5/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.